IASO BioTherapeutics（驯鹿生物） Email Formats

Biotechnology Research • Shanghai, China • 21-50 Employees

IASO BioTherapeutics（驯鹿生物） Email Formats

IASO BioTherapeutics（驯鹿生物） uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@iasobio.com), used 57.9% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@iasobio.com	57.9%
{first name}.{last name}	john.doe@iasobio.com	42.1%

Key Contacts at IASO BioTherapeutics（驯鹿生物）

Min Zhang

Director Of Business Development

Gang Hu

Senior Director, Project Leader

Guang Hu

Executive Director

Claire Shelby

Sr. Director, Clinical Operations

Lili Chen

Vice Director Of Strategy Information

David Yao

Director, Head Of Biometrics

Claire Shelby

Sr. Director, Clinical Operations

Company overview

Headquarters	Shanghai, China
Phone number	+862558287610
Website	iasobio.com
NAICS	541714
SIC	873
Keywords	Cell Therapy, Biologics, Gene Editing, Antibody Discovery
Founded	2017
Employees	21-50
Socials

About IASO BioTherapeutics（驯鹿生物）

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of 8 novel pipeline products, as well as IASO’s leading asset, CT103A, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM), which was granted Breakthrough Therapeutic Designation by China’s National Medical Products Administration (NMPA) in February 2021. In addition. The company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy, has received two IND clearances from NMPA for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in July 2021. For more information on IASO Bio, please visit www.iasobio.com.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

Director

Employees by Department

IASO BioTherapeutics（驯鹿生物） has 13 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore IASO BioTherapeutics（驯鹿生物）'s funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-02-17	6	$73,800,000
2024-08-05	19	N/A

Funding Insights

$73,800,000

Total funding amount

Number of funding rounds

IASO BioTherapeutics（驯鹿生物） Tech Stack

Discover the technologies and tools that power IASO BioTherapeutics（驯鹿生物）'s digital infrastructure, from frameworks to analytics platforms.

jQuery

JavaScript libraries

Nginx

Reverse proxies

PHP

Programming languages

Sectigo

SSL/TLS certificate authorities

Swiper

JavaScript libraries

Animate.css

UI frameworks

AOS

JavaScript libraries

Frequently asked questions

IASO BioTherapeutics（驯鹿生物） is located in Shanghai, CN.

You can reach IASO BioTherapeutics（驯鹿生物） at +862558287610.

IASO BioTherapeutics（驯鹿生物） was founded in 2017, making it 9 years old. The company has established itself as a significant player in its industry over this time.

IASO BioTherapeutics（驯鹿生物） has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

IASO BioTherapeutics（驯鹿生物） has raised a total of $73,800,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at IASO BioTherapeutics（驯鹿生物）

Min Zhang

Director Of Business Development

Gang Hu

Senior Director, Project Leader

Guang Hu

Executive Director

Claire Shelby

Sr. Director, Clinical Operations

Lili Chen

Vice Director Of Strategy Information

David Yao